Biosimilars have important cost benefits to offer the overall
healthcare system, and they give access to treatment for
patients with rare or very serious illnesses that can benefit
from biologics. At the same time, however, biosimilars are very
new to market, and so there is much still to learn about their
safety profiles. Barbara Testa, at ProductLife Group, explores
biosimilarsâ€™ potential â€” and challenges.